Santos, Fabio P. S. http://orcid.org/0000-0001-8573-9493
Getta, Bartlomiej
Masarova, Lucia
Famulare, Christopher
Schulman, Jessica
Datoguia, Tarcila S.
Puga, Renato D. http://orcid.org/0000-0002-6366-0765
Alves Paiva, Raquel de Melo
Arcila, Maria E.
Hamerschlak, Nelson http://orcid.org/0000-0002-5140-5310
Kantarjian, Hagop M.
Levine, Ross L.
Campregher, Paulo Vidal
Rampal, Raajit K.
Verstovsek, Srdan
Article History
Received: 29 April 2019
Revised: 30 July 2019
Accepted: 28 August 2019
First Online: 18 October 2019
Compliance with ethical standards
:
: HMK and SV have received research funding from Incyte Corp. SV has received research funding from Roche, NS Pharma, Celgene, Gilead, Promedior, CTI Biopharma Corp, Genentech, Blueprint Medicines Corp, and Novartis. SV has served as a consultant for Incyte Corp, Constellation, Pragmatist, Sierra, Novartis, Celgene. RKR has received consulting fees from Incyte corporation, Celgene corporation, Agios Pharmaceuticals, Apexx oncology, BeyondSpring, Partner Therapeutics, and Jazz Pharmaceuticals, and has received research funding from Constellation pharmaceuticals, Incyte corporation, and Stemline Therapeutics. FPSS and NH have received research funding from Novartis, Inc. FPSS served as a consultant and speaker for Novartis, Inc. The other authors declare that they have no conflict of interest.